FOXP3 and steatosis: Several parameters distinguished patients with simple steatosis at the early MASLD stage from those with steatosis with inflammation – advanced MASLD, including Foxp3+ [% of CD4+CD25+]; IL-10 [MFI in CD4+ and CD4+CD25+ populations] (Figures 2A, C, D).